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IMMUNE-CHECKPOINT INHIBITORS: CLINICAL EVI-
DENCE AND LIMITATIONS 
 The Nobel Prize of Medicine in 2018 awarded jointly 
by James P. Allison and Tasuku Honjo was an important 
landmark recognizing recent clinical advances in immune-
oncology. Targeting the immune system to fight cancer is 
not a new concept, but there were few significant clinical 
advances until very recently. 
 Tasuku Honjo et al first reported programmed cell death 
protein 1 (PD-1) in 1992, a protein expressed on the sur-
face of T-cells that acts as a brake in T-cells cytotoxicity.1 So 
blocking PD-1 could facilitate T-cells activity against cancer. 
 In 1996 James P. Allison et al discovered that the cy-
totoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a 
regulator of T-cells activity, transmitting signals that inhibits 
its activation and proliferation,2 thus, blocking CTLA4 could 
improve T-cells activity against cancer.
 These concepts were further explored with immune 
checkpoint inhibitors (ICI) anti-PD-1 and anti-CTLA-4, 
against cancer. Compared with classic chemotherapy, 
checkpoint inhibitors might take more time to be effective, 
but those who benefit are normally long-term responders 
(Fig. 1). The toxicity profile is globally more favorable com-
pared with chemotherapy, with immune related adverse 
events being the major toxicity of concern but that is usually 
manageable with immune-modulators such as steroids and/
or treatment interruption.
 Immune checkpoint inhibitors changed the panorama of 
metastatic melanoma dramatically, from a terrible prognosis 
and no efficacious treatment to 34% to 58% long term sur-
vivals.3,4 
 Further studies confirmed the benefit of checkpoint in-
hibitors across different types of cancers such as in lung, 
bladder, kidney, Merkel cell carcinoma, head and neck, lym-
phomas among others. Results are not so impressive like in 
metastatic melanoma, but it is still very positive to change 
the gold standard of treatment of those diseases in some 
settings.
 Moreover, the combination between different checkpoint 
inhibitors could improve clinical outcomes. In checkmate 
067 clinical trial, in advanced melanoma patients, the over-
all survival rate at three years was 58% for nivolumab (an-
ti-PD-1) plus ipilimumab (anti-CTLA-4) group, 52% in the 
nivolumab group and 34% in the ipilimumab group.3 In ad-
vanced renal cell carcinoma, the overall survival and objec-
tive response rates were significantly higher with nivolumab 
plus ipilimumab vs sunitinib, which was the previous stand-
ard of care in this setting5 (Table 1).
 Despite the achieved clinical results so far, the majority 
of patients treated do not benefit from immune checkpoint 
inhibitors, and there is still lack of evidence on predictors 
of (non) benefit. Therefore, it is very important to find more 
strategies to improve immune-oncology results, combining 
treatments with checkpoint inhibitors or developing other 
novel immune-oncology strategies (Fig. 2).
NOVEL IMMUNE-ONCOLOGY STRATEGIES 
“Next-generation” immune checkpoints and co-stimu-
latory monoclonal antibodies
 Three signals are needed for T-cell activation. The first 
signal happens when antigen-presenting cells (APCs) pre-
sent the antigen through MHC to T cell receptor (TCR) on 
T cells. The second signal occurs with the interaction be-
tween co-stimulatory receptors on T cells and their respec-
tive signals on APCs. Finally, the third signal comes from 
cytokines. Co-inhibitory (immune checkpoints) and co-stim-
ulatory receptors are key for signal two, and their balance 
will determine T-cell activation.6
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 The co-inhibitory receptors, CTLA-4 and PD-1, have 
been described to be responsible for maintaining overall 
immune self-tolerance, while “next-generation” immune 
checkpoints, including T-cell immunoglobulin and mucin-
domain containling-3 (Tim-3), lymphocyte activation gene-
3 (Lag-3) and T-cell immunoreceptor with Ig and ITIM do-
mains (TIGIT), have more specific roles in tolerance. These 
three co-inhibitory receptors are highly expressed on the 
dysfunctional and exhausted T cells and NK cells.7,8 Preclin-
ical data have shown anti-tumor activity of monoclonal anti-
bodies against these receptors,9-11 and now these drugs are 
currently being studied in clinical trials for hematologic and 
solid tumors, either alone (NCT03489369; NCT03489343; 
NCT01968109), or in combination with anti-CTLA-4 and/or 
anti-PD-1 therapy (Table 1).
 Co-stimulatory receptors, including 4-1BB, glucocorti-
coid-induced TNFR-related protein (GITR) and OX40 pro-
mote T cells survival, activation and proliferation. Studies 
performed in different pre-clinical models using agonistic 
monoclonal antibodies targeting these receptors in combi-
nation with anti-PD-1 have shown non-consistent results.12,13 
While more work needs to be done in this field to better un-
derstand the mechanism of action of these antibodies, the 
first clinical trials using these agents, alone or in combina-
tion with anti-CTLA-4 and/or anti-PD-1, in cancer patients 
are ongoing and their results are awaited (NCT01239134; 
NCT03126110; NCT03241173).
Adoptive cell therapy
 Adoptive cell therapy (ACT) uses tumor-infiltrating lym-
phocytes (TILs) extracted from fresh tumor samples, or pe-
ripheral blood lymphocytes (leukapheresis). After extracting 
these lymphocytes, there is a selection of the ones express-
ing T cell receptor (TCR) targeting a specific tumor antigen, 
or they can be genetically engineered to express the de-
sired TCR. These lymphocytes are expanded and activated 
ex vivo, and then infused into the patients, after lymphode-
pletion to eliminate regulatory T cells.14,15
 In a National Cancer Institute (NCI) clinical trial, meta-
static melanoma patients were previously subjected to total 
body irradiation (TBI - 2 Gy or 12Gy) and to a non-mye-
loablative regimen with fludarabine and cyclophosphamide, 
while the cells were expanded with the T-cell stimulating an-
ti-CD3 monoclonal antibody (OKT3) and IL-2. In this study, 
objective responses were observed in 49% to 72% depend-
ing on the conditioning regimen prior to the cells’ infusion. 
Figure 1 – Survival: curve with immune checkpoint inhibitors
1 – Later response with ICI - Chemotherapy has a rapid cytotoxicity and tumor reduction effect. ICI monotherapy requires some weeks to 
months to start having effect; 2 – Median is a bad outcome:  Median OS or PFS are current outcomes used in oncology clinical trials, but 
due to the delay but long term effect with ICI, it is important to find other outcomes which better capture the magnitude of benefit with ICIs; 
3 – Long term responders: Those who benefit from ICIs are normally long term responders, having a chronic disease or perhaps being 
cured
* Ilustrative time. Time changes with different types of cancer.
Su
rv
iv
al
 (%
)
Time (months)
Combination or sequence plus predictors of response
Combination or sequence of treatment
Checkpoint inhibitors monotherapy
Chemotherapy
10%
0 6 12 18 24 30 36*
50%
100%
1
2
3
Castelo-Branco L, et al. Promising immuno-oncology treatments beyond the 2018 Nobel prize, Acta Med Port 2019 Apr;32(4):251-257
PE
R
SP
EC
TI
VA
Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                253
Even though these results are promising, this was a single 
arm trial with no randomized comparison.16 Moreover, there 
are some obstacles to this technique that need to be ad-
dressed in order to increase its efficacy, including the im-
munosuppressive tumor microenvironment and the lack of 
automation in the ACT production process, as it is a highly 
personalized treatment, is labor-intensive and requires 
laboratory expertise.15 This strategy is now being tested in 
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Table 1 – Selection of clinical trials with Immune checkpoint inhibitors combinations
Combination Tumour type Cohorts Outcome(mPFS) Clinical Trial Reference
ICI + ICI Advanced
melanoma
(1st line)
Advanced
RCC
(1st line)
Solid tumors 
(> 1st line)
Ipilimumab
Nivolumab
Ipilimumab + Nivolumab
Sunitinib
Ipilimumab + Nivolumab
Relatlimab*
Relatlimab + Nivolumab
2.9 mo
6.9 mo
11.5 mo
8.4 mo
11.6 mo
Recruiting
Checkmate-067
Phase 3
Checkmate-214
Phase 3
Phase 1/2
Wolchok JD, 2017
Motzer RJ, 2018
NCT01968109
ICI + 
Costimulatory 
agonist
Gastric cancer, 
SCCHN, NSCLC 
or advanced RCC 
Refractory to prior 
PD-1/L1 therapy
INCAGN01876§ + Nivolumab
INCAGN01876 + Ipilimumab
INCAGN01876 + Nivolumab + Ipilimumab
INCAGN01949§§ + Nivolumab
INCAGN01949 + Ipilimumab
INCAGN01949 + Nivolumab + Ipilimumab
Recruiting
Recruiting
Phase 1/2
Phase 1/2
NCT03126110
NCT03241173
ICI + Adoptive 
cell therapy
Advanced
melanoma
(any line)
Adoptive cell transfer + Ipilimumab Active, not 
recruiting
Phase 2 NCT02027935
ICI + Vaccines Advanced
pancreatic cancer
(any line & no 
previous PD1 or 
CTLA4 treatment)
HPV-16-Positive 
incurable 
solid tumors
Nivolumab + Ipilimumab
Nivolumab + Ipilimumab + 
GVAX ‡ Pancreas vaccine
Nivolumab + ISA 101¶ 
Recruiting
Active, not 
recruiting
Phase 2
Phase 2
NCT03190265
NCT02426892
ICI + Oncolytic 
Virus
Advanced
melanoma
(1st line of previous 
BRAFi/MEKi)
Pembrolizumab + TVEC Active, not 
recruiting
Keynote-034 Phase 3 NCT02263508
ICI + 
Radiotherapy
NSCLC
locally advanced, 
unresectable
SCCHN
locally advanced 
Chemoradiotherapy + Durvalumab
Chemoradiotherapy + Placebo
Pembrolizumab + Radiotherapy
Cetuximab + Radiotherapy
16.8 mo 
5.6 mo
Active, not 
recruting
PACIFIC
Phase 3
Phase 2
Antonia SJ, 2017
NCT02707588
ICI + 
Chemotherapy
NSCLC
nonsquamous
metastatic
(1st line)
TNBC
metastatic
Chemotherapy + Pembrolizumab
Chemotherapy + Placebo
Nab-paclitaxel + Atezolizumab
Nab-paclitaxel + Placebo
8.8 mo
4.9 mo
7.2 mo
5.5 mo
KEYNOTE 189
Phase 3
IMpassion130 Phase 3 
Gandhi L, 2018
Schmid P, 2018
ICI + small 
molecules
Advanced RCC
NSCLC
locally advanced 
or metastatic
Axetinib + Avelumab
Sunitinib
Avelumab + Crizotinib
Avelumab + PF-06463922 ¶ ¶
13.8 mo
8.4 mo
Active, not 
recruiting
JAVELIN renal 101
Phase 3
Javelin Lung 101
Phase 2
Motzer RJ, 2018
NCT02584634
mPFS: median progression free survival in months; ICI: immune checkpoint inhibitors; mo: months; SCCHN: squamous cell carcinoma of head and neck; NSCLC: non small cell lung 
cancer; RCC: renal cell carcinoma; TNBC: triple negative breast cancer; TVEC: talimogene Laherparepvec (oncolytic herpes virus);
* Relatlimab - anti-LAG-3; § INCAGN01876 - anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic humanized monoclonal antibody; §§ INCAGN01949 - 
anti-human OX-40 agonistic monoclonal antibody; ‡ GVAX- cancer vaccine; ¶  ISA101 - HPV-16 vaccination; ¶ ¶ PF-06463922 - dual ALK/ROS1 inhibitor
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Figure 2 – Novel immune-oncology strategies 
(A) ‘Next-generation’ immune checkpoint modulators: After positive results with anti-pd1 or anti pd-l1 drugs, blocking other checkpoint 
inhibitors (eg. LAG-3, TIM-3, TIGIT), or activate co-stimulators (eg.OX-40, 4-1BB, GITR) are promising immune-oncology strategies on 
clinical research. 
(B) Adoptive cell therapy. 1 – Extraction of tumor-infiltrating lymphocytes (TILs) or lymphocytes from peripheral blood; 2 – Selection of TILs 
targeting a specific tumor antigen, or engineering of lymphocytes to express a desired antigen receptor - Chimeric antigen receptor T cells 
(CAR T cells); 3 – Expansion of T cells; 4 – Infusion of T-Cells for a specific immune-reaction against cancer. 
(C) Vaccines: 1 – Cytotoxic treatments (e.g. chemotherapy or radiotherapy) can induce tumor lysis and antigens release to be recognized 
by immune-system; 2 – Some tumor particles (proteins or glucosides), when injected on a tumor-naive patient, might induce immunization 
against those tumors, and combination with immune-stimulator agents could improve such benefit; 3 – Dendritic cells are collected, 
exposed ex-vivo to tumor antigens and growth factors to become mature and further infused to induce immunization against cancer.
(D) Oncolytic virus: 1 – Local administration of oncolytic virus on tumor site; 2 – Selective infection of tumor cells by oncolytic virus 
(e.g. T-VEC in melanoma); 3 – Replication of virus inside tumor cells; 4 – Tumor lysis and antigen release. Immune system (innate and 
adaptative) could more easily recognize tumor antigens; 5 – Oncolytic virus could infect more local tumor cells, but the benefit on distant 
lesions it is still unknown and remains a challenge.
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combination with ipilimumab in a phase II trial for advanced 
melanoma patients (Table 1).
 Adoptive transfer of T cells engineered with TCRs or 
chimeric antigen receptors (CARs) is a strategy to improve 
the efficacy of the anti-tumor response. The TCR therapy 
consists of the isolation of normal circulating T-cells from 
the patient’s blood and genetically modified via transfection. 
CARs, which consist of the combination of an antibody and 
a TCR, are antigen specific and their activation is not de-
pendent on MHC expression on tumor cells. CAR-T cells 
therapy has been particularly successful in hematologic 
cancers, including the CTL019 for young adult B-ALL pa-
tients17 (Grupp, 2016) and the CT019 for refractory aggres-
sive NHL.18 
Vaccines
 The goal of cancer vaccination is to induce an efficient 
antigen presentation generating an anti-tumor response, 
based on CD4+ and CD8+ T lymphocytes against tumor-
specific antigens, that is sufficiently robust to be able to 
produce long-lasting clinical responses. Different strategies 
have been studied including: (1) non-targeted vaccines, us-
ing non-specific strategies to induce an immunogenic tumor 
cell death, including radiotherapy, some chemotherapies 
or administration of tumor specific antigens to induce im-
munization against tumor; (2) ex vivo generated dendritic 
cells (DCs), including activation, expansion and reinfusion 
of DCs into the patient; (3) in vivo DC targeting.19 
 Sipuleucel-T is the only cancer vaccine approved by the 
FDA. This vaccine consists of autologous peripheral blood 
mononuclear cells (PBMC) obtained by leukapheresis and 
cultured with the fusion protein that combines recombinant 
PAP with recombinant granulocyte-macrophage colony-
stimulating factor (GM-CSF). In a phase III trial (Impact 
trial), 512 men with metastatic castration-resistant prostate 
cancer were randomly assigned to receive either the vac-
cine Sipuleucel-T or placebo. This trial showed a relative 
reduction of 22% in the risk of death in the Sipuleucel-T 
group as compared with the placebo group (hazard ratio, 
0.78; 95% confidence interval [CI], 0.61 to 0.98; p = 0.03). 20 
Different types of vaccines are now being tested in combi-
nation with anti-CTLA-4 and/or anti-PD-1 for different tumor 
types (Table 1).
Oncolytic virus
 Oncolytic viruses, like vaccines, stimulate antigen pres-
entation and generate an anti-tumor response. Oncolytic 
viruses infect/invade, replicate within and kill tumor cells, 
inducing antigen release and promoting a pro-inflammatory 
environment. The only FDA approved oncolytic virus is the 
T-VEC (talimogenelaherparepvec), consisting of attenuated 
herpes simplex virus (HSV) associated with GM-CSF. T-
VEC was studied in a phase III trial (2:1) with 436 unresect-
able stage IIIA/B/C melanoma patients. The T-VEC or the 
GM-CSF alone were injected into the tumor, with an overall 
objective response of 26.4% and 5.7% for the arms of the 
T-VEC and GM-CSF, respectively.21 Even though the results 
seem compelling, in order to fully understand the effect of 
T-VEC, as well as other intralesional agents, it would be 
important to study the effect of these intralesional agents 
on the non-injectable lesions. T-VEC is now being studied 
alone or in different combinations, including immune check-
points, radiotherapy and chemotherapy (NCT03086642; 
NCT02263508; NCT03554044). An important challenge 
ahead with oncolytic virus is to have a very selective infec-
tion on tumor cells, without their recognition/destruction by 
the immune-system, thus optimizing the clinical benefit also 
on distant metastasis, without major side-effects.
Bifunctional agents
 This new immunotherapy strategy refers to bispecific an-
tibodies that bind to two different antigens with high affinity. 
Bispecific T-cell engagers (BiTE’s) are a particular type of 
bispecific antibodies that bind to CD3+ cells and to a tumor 
specific antigen. The first BiTE to be approved by the FDA 
was Blinatumomab for B-cell acute lymphoblastic leukemia 
(B-ALL). Blinatumomab binds to CD3, expressed by T cells, 
and to CD19, expressed by B cells. In a phase II trial, blina-
tumomab showed impressive clinical activity, inducing 43% 
complete responses in refractory B-ALL patients22. Some 
of the advantages of BiTE’s include the cytotoxic capacity 
and the ability to bind to tumor cells expressing low antigen 
levels.23
COMBINATION OF CHECKPOINT INHIBITORS WITH 
CLASSIC TREATMENTS 
 There are different combinations between checkpoint 
inhibitors and other treatment strategies being tested (Ta-
ble 1), and that includes combination with ‘older’ oncology 
treatments such as chemotherapy, radiotherapy or small 
molecules.
Checkpoint inhibitors plus radiotherapy
 Different doses of ionizing radiation can have an im-
munosuppressive or immune-stimulator effect.24 There-
fore, finding optimal schemes combining radiotherapy with 
checkpoint inhibitors is crucial to optimize this synergic ben-
efit. Different clinical studies showed an increased response 
rate for patients receiving combination of radiotherapy with 
ICI, with no significant increase in toxicity25-27 and there is a 
growing number of clinical trials addressing combination or 
sequence between radiotherapy and immunotherapy. The 
best combination or sequence of treatment, radiotherapy 
doses and fraction schedules across different tumor types, 
are still important challenges to be addressed.
Checkpoint inhibitors with chemotherapy
 Chemotherapy is still the gold-standard in many oncol-
ogy settings, and there is a strong interest to combine it 
with ICI. Chemotherapy can have a myelosuppressive ef-
fect or stimulate the immune system by different mecha-
nisms,28 depending on doses, type of chemotherapy, type 
of cancer, among other factors. Thus, it is very important 
to optimize these combination strategies to gain clinical 
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benefit. In non-squamous, non-small-cell lung cancer, the 
addition of pembrolizumab to standard chemotherapy im-
proved OS and PFS comparing with chemotherapy alone.29 
Also, in metastatic triple negative breast cancer, atezoli-
zumab plus nab-paclitaxel increased the median PFS and 
mainly OS in PD-L1 positive immune cells infiltrating the 
tumor  compared with nab-paclitaxel plus placebo.30 There 
are many ongoing clinical trials combining chemotherapy 
with checkpoint inhibitors and more positive results can be 
expected in a near future.
Checkpoint inhibitors with small molecules
 Some small molecules, such as tyrosine kinase inhibi-
tors (TKIs) can block important intracellular signaling path-
ways for tumor growth and survival. These drugs have been 
widely used across different tumor types, such as leukemia, 
lung, renal, breast cancers, among others. With these drugs 
a tumor response  can be expected, but due to drug resist-
ance clones there is also a high rate of relapse. There is a 
strong rationale to combine TKIs with ICI, having the benefit 
of faster TKIs response and potentially long term responses 
with ICIs. In advanced renal cell carcinoma, axitinib plus 
avelumab (TKI+ICI) significantly improved PFS versus the 
standard of care sunitinib,31 thus becoming a possible first-
line treatment for this setting. There are many ongoing dif-
ferent trials combining TKIs plus ICIs in different tumor set-
tings and results are awaited (Table 1).
FUTURE PERSPECTIVES 
 Despite positive results achieved with immune check-
point inhibitors, decreasing the number of non-responders 
and improving clinical results is still an important challenge 
ahead.
 Finding reliable predictors of response is an important 
goal for the near future, and that can be very helpful to se-
lect those who might benefit and to identify those who will 
not respond to the available drugs. 
 Novel immune-oncology strategies and combination 
with other treatment strategies are showing promising re-
sults, and there is a strong rationale to expect more positive 
results in a near future. 
 Moreover, the identification of new mechanisms of re-
sistance to ICI and new therapeutic targets makes it im-
perative to help this significant proportion of patients that do 
not benefit from available immunotherapy strategies.
 Finally, a more personalized research, with the identi-
fication of more subgroups of disease (e.g., MSI positive 
solid tumors) can be helpful to select specific treatment 
strategies towards a tendentially more personalized im-
mune-oncology medicine.
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